Medical device company R3 Vascular Inc., a Mountain View, CA-based developer of novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), has announced the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs. Image courtesy: R3 Vascular Inc.
July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), has announced the appointment of Josh Smale as its Vice President of Global Clinical and Scientific Affairs.
Prior to joining R3 Vascular, Smale served as Vice President of Clinical Affairs for the Peripheral Intervention business unit of Becton Dickinson (BD) where he was responsible for all aspects of clinical evidence generation and dissemination for the company’s complex and diverse device portfolio, according to a written statement detailing the appointment. Prior to his tenure at BD, Smale served in roles of increasing responsibility for Bard Peripheral Vascular, Inc. (BPV) which was acquired by BD, and as Regulatory Affairs Manager for SenoRX, Inc. which was acquired by BPV. Additionally, he served as Regulatory Affairs Manager for Endologix, Inc. and in various roles at BPV, served on the board of the Peripheral Intervention business unit of BD, has received numerous awards, is the co-author of several publications, and holds five Vena Cava Filter patents.
“Josh has a proven track record and more than 20 years of relevant medical device experience specializing in clinical and regulatory affairs strategy, clinical evidence generation and dissemination, and physician education,” said Christopher M. Owens, President and CEO of 3 Vascular, headquartered in Mountain View, CA. Owens added, “Among other key clinical and scientific affairs programs, Josh will lead our clinical trial efforts, including our pivotal ELITE trial for our next generation Magnitude drug eluting bioresorbable scaffold.”
R3 Vascular is a privately-held medical device company that develops a novel technology platform for the next generation of fully bioresorbable drug eluting sirolimus coated vascular scaffolds. The company reports these are designed to deliver the ‘stent-like’ support of a scaffold along with the anti-inflammatory and anti-proliferative result of sirolimus, but ‘disappearing’ over time as the vessel heals.
More information: www.r3vascular.com
March 23, 2026 
